Phase I multicenter trial of CUDC-907 in children and young adults with relapsed/refractory solid tumors, CNS tumors, and lymphomas.

Authors

null

David Stephen Shulman

Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA

David Stephen Shulman , Cecilia Carlowicz , Clay Gustafson , Kieuhoa Tran Vo , Elizabeth Fox , Jodi Ann Muscal , Jeffrey G. Supko , Andrew E. Place , Susan N. Chi , Suzanne Shusterman , Gina Hanna , Jane O'Brien , Suzanne Ezrre , Pei-Chi Kao , Wendy B. London , Steven G. DuBois

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Pediatric Solid Tumors

Clinical Trial Registration Number

NCT02909777

Citation

J Clin Oncol 36, 2018 (suppl; abstr 10542)

DOI

10.1200/JCO.2018.36.15_suppl.10542

Abstract #

10542

Poster Bd #

215

Abstract Disclosures

Similar Posters

First Author: David Stephen Shulman

Poster

2023 ASCO Annual Meeting

Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.

Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.

First Author: Brian Ko

First Author: Patricia LoRusso

First Author: Todd Michael Bauer